Functional analysis of a novel glioma antigen, EFTUD1

Katsuya Saito, Yukihiko Iizuka, Shigeki Ota, Satoshi Takahashi, Kenta Nakamura, Hideyuki Saya, Kazunari Yoshida, Yutaka Kawakami, Masahiro Toda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

BACKGROUND: A cDNA library made from 2 glioma cell lines, U87MG and T98G, was screened by serological identification of antigens by recombinant cDNA expression (SEREX) using serum from a glioblastoma patient. Elongation factor Tu GTP binding domain containing protein 1 (EFTUD1), which is required for ribosome biogenesis, was identified. A cancer microarray database showed overexpression of EFTUD1 in gliomas, suggesting that EFTUD1 is a candidate molecular target for gliomas.

METHODS: EFTUD1 expression in glioma cell lines and glioma tissue was assessed by Western blot, quantitative PCR, and immunohistochemistry. The effect on ribosome biogenesis, cell growth, cell cycle, and induction of apoptosis and autophagy in glioma cells during the downregulation of EFTUD1 was investigated. To reveal the role of autophagy, the autophagy-blocker, chloroquine (CQ), was used in glioma cells downregulating EFTUD1. The effect of combining CQ with EFTUD1 inhibition in glioma cells was analyzed.

RESULTS: EFTUD1 expression in glioma cell lines and tissue was higher than in normal brain tissue. Downregulating EFTUD1 induced G1 cell-cycle arrest and apoptosis, leading to reduced glioma cell proliferation. The mechanism underlying this antitumor effect was impaired ribosome biogenesis via EFTUD1 inhibition. Additionally, protective autophagy was induced by glioma cells as an adaptive response to EFTUD1 inhibition. The antitumor effect induced by the combined treatment was significantly higher than that of either EFTUD1 inhibition or CQ alone.

CONCLUSION: These results suggest that EFTUD1 represents a novel therapeutic target and that the combination of EFTUD1 inhibition with autophagy blockade may be effective in the treatment of gliomas.

Original languageEnglish
Pages (from-to)1618-1629
Number of pages12
JournalNeuro-Oncology
Volume16
Issue number12
DOIs
Publication statusPublished - 2014 Dec 1

Fingerprint

Glioma
Antigens
Autophagy
Chloroquine
Ribosomes
Down-Regulation
Cell Line
Peptide Elongation Factor Tu
Apoptosis
G1 Phase Cell Cycle Checkpoints
Glioblastoma
Guanosine Triphosphate
Gene Library
Cell Cycle
Therapeutics
Complementary DNA
Western Blotting
Immunohistochemistry
Cell Proliferation
Databases

Keywords

  • autophagy
  • EFTUD1
  • glioma
  • ribosome biogenesis
  • SEREX

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Functional analysis of a novel glioma antigen, EFTUD1. / Saito, Katsuya; Iizuka, Yukihiko; Ota, Shigeki; Takahashi, Satoshi; Nakamura, Kenta; Saya, Hideyuki; Yoshida, Kazunari; Kawakami, Yutaka; Toda, Masahiro.

In: Neuro-Oncology, Vol. 16, No. 12, 01.12.2014, p. 1618-1629.

Research output: Contribution to journalArticle

Saito, Katsuya ; Iizuka, Yukihiko ; Ota, Shigeki ; Takahashi, Satoshi ; Nakamura, Kenta ; Saya, Hideyuki ; Yoshida, Kazunari ; Kawakami, Yutaka ; Toda, Masahiro. / Functional analysis of a novel glioma antigen, EFTUD1. In: Neuro-Oncology. 2014 ; Vol. 16, No. 12. pp. 1618-1629.
@article{094c2f1f00d040ff8bada7f904db8a8f,
title = "Functional analysis of a novel glioma antigen, EFTUD1",
abstract = "BACKGROUND: A cDNA library made from 2 glioma cell lines, U87MG and T98G, was screened by serological identification of antigens by recombinant cDNA expression (SEREX) using serum from a glioblastoma patient. Elongation factor Tu GTP binding domain containing protein 1 (EFTUD1), which is required for ribosome biogenesis, was identified. A cancer microarray database showed overexpression of EFTUD1 in gliomas, suggesting that EFTUD1 is a candidate molecular target for gliomas.METHODS: EFTUD1 expression in glioma cell lines and glioma tissue was assessed by Western blot, quantitative PCR, and immunohistochemistry. The effect on ribosome biogenesis, cell growth, cell cycle, and induction of apoptosis and autophagy in glioma cells during the downregulation of EFTUD1 was investigated. To reveal the role of autophagy, the autophagy-blocker, chloroquine (CQ), was used in glioma cells downregulating EFTUD1. The effect of combining CQ with EFTUD1 inhibition in glioma cells was analyzed.RESULTS: EFTUD1 expression in glioma cell lines and tissue was higher than in normal brain tissue. Downregulating EFTUD1 induced G1 cell-cycle arrest and apoptosis, leading to reduced glioma cell proliferation. The mechanism underlying this antitumor effect was impaired ribosome biogenesis via EFTUD1 inhibition. Additionally, protective autophagy was induced by glioma cells as an adaptive response to EFTUD1 inhibition. The antitumor effect induced by the combined treatment was significantly higher than that of either EFTUD1 inhibition or CQ alone.CONCLUSION: These results suggest that EFTUD1 represents a novel therapeutic target and that the combination of EFTUD1 inhibition with autophagy blockade may be effective in the treatment of gliomas.",
keywords = "autophagy, EFTUD1, glioma, ribosome biogenesis, SEREX",
author = "Katsuya Saito and Yukihiko Iizuka and Shigeki Ota and Satoshi Takahashi and Kenta Nakamura and Hideyuki Saya and Kazunari Yoshida and Yutaka Kawakami and Masahiro Toda",
year = "2014",
month = "12",
day = "1",
doi = "10.1093/neuonc/nou132",
language = "English",
volume = "16",
pages = "1618--1629",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Functional analysis of a novel glioma antigen, EFTUD1

AU - Saito, Katsuya

AU - Iizuka, Yukihiko

AU - Ota, Shigeki

AU - Takahashi, Satoshi

AU - Nakamura, Kenta

AU - Saya, Hideyuki

AU - Yoshida, Kazunari

AU - Kawakami, Yutaka

AU - Toda, Masahiro

PY - 2014/12/1

Y1 - 2014/12/1

N2 - BACKGROUND: A cDNA library made from 2 glioma cell lines, U87MG and T98G, was screened by serological identification of antigens by recombinant cDNA expression (SEREX) using serum from a glioblastoma patient. Elongation factor Tu GTP binding domain containing protein 1 (EFTUD1), which is required for ribosome biogenesis, was identified. A cancer microarray database showed overexpression of EFTUD1 in gliomas, suggesting that EFTUD1 is a candidate molecular target for gliomas.METHODS: EFTUD1 expression in glioma cell lines and glioma tissue was assessed by Western blot, quantitative PCR, and immunohistochemistry. The effect on ribosome biogenesis, cell growth, cell cycle, and induction of apoptosis and autophagy in glioma cells during the downregulation of EFTUD1 was investigated. To reveal the role of autophagy, the autophagy-blocker, chloroquine (CQ), was used in glioma cells downregulating EFTUD1. The effect of combining CQ with EFTUD1 inhibition in glioma cells was analyzed.RESULTS: EFTUD1 expression in glioma cell lines and tissue was higher than in normal brain tissue. Downregulating EFTUD1 induced G1 cell-cycle arrest and apoptosis, leading to reduced glioma cell proliferation. The mechanism underlying this antitumor effect was impaired ribosome biogenesis via EFTUD1 inhibition. Additionally, protective autophagy was induced by glioma cells as an adaptive response to EFTUD1 inhibition. The antitumor effect induced by the combined treatment was significantly higher than that of either EFTUD1 inhibition or CQ alone.CONCLUSION: These results suggest that EFTUD1 represents a novel therapeutic target and that the combination of EFTUD1 inhibition with autophagy blockade may be effective in the treatment of gliomas.

AB - BACKGROUND: A cDNA library made from 2 glioma cell lines, U87MG and T98G, was screened by serological identification of antigens by recombinant cDNA expression (SEREX) using serum from a glioblastoma patient. Elongation factor Tu GTP binding domain containing protein 1 (EFTUD1), which is required for ribosome biogenesis, was identified. A cancer microarray database showed overexpression of EFTUD1 in gliomas, suggesting that EFTUD1 is a candidate molecular target for gliomas.METHODS: EFTUD1 expression in glioma cell lines and glioma tissue was assessed by Western blot, quantitative PCR, and immunohistochemistry. The effect on ribosome biogenesis, cell growth, cell cycle, and induction of apoptosis and autophagy in glioma cells during the downregulation of EFTUD1 was investigated. To reveal the role of autophagy, the autophagy-blocker, chloroquine (CQ), was used in glioma cells downregulating EFTUD1. The effect of combining CQ with EFTUD1 inhibition in glioma cells was analyzed.RESULTS: EFTUD1 expression in glioma cell lines and tissue was higher than in normal brain tissue. Downregulating EFTUD1 induced G1 cell-cycle arrest and apoptosis, leading to reduced glioma cell proliferation. The mechanism underlying this antitumor effect was impaired ribosome biogenesis via EFTUD1 inhibition. Additionally, protective autophagy was induced by glioma cells as an adaptive response to EFTUD1 inhibition. The antitumor effect induced by the combined treatment was significantly higher than that of either EFTUD1 inhibition or CQ alone.CONCLUSION: These results suggest that EFTUD1 represents a novel therapeutic target and that the combination of EFTUD1 inhibition with autophagy blockade may be effective in the treatment of gliomas.

KW - autophagy

KW - EFTUD1

KW - glioma

KW - ribosome biogenesis

KW - SEREX

UR - http://www.scopus.com/inward/record.url?scp=84935431925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935431925&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nou132

DO - 10.1093/neuonc/nou132

M3 - Article

VL - 16

SP - 1618

EP - 1629

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 12

ER -